A. Chlistalla
Impact in
- Oncology top 5%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Research top 10%
- Breast Cancer Treatment Studies
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Advanced Breast Cancer Therapies 3
- Oncology 4
- Cancer Treatment and Pharmacology 4
- Colorectal Cancer Treatments and Studies 2
- Co-authors
- David Miles (1 shared paper)Andrew Wardley (1 shared paper)Andreas Schneeweiß (2 shared papers)Arlene Chan (1 shared paper)Xavier Pivot (1 shared paper)Joohyuk Sohn (1 shared paper)Piotr Tomczak (1 shared paper)T. Delozier (1 shared paper)
- Journals
- Cancer Research (2 papers)Journal of Clinical Oncology (1 paper)Circulation (1 paper)Circulation Research (1 paper)Blood (1 paper)
- Partner nations
- United KingdomGermanySwitzerland
In The Last Decade
A. Chlistalla
7 papers receiving 799 citations
A. Chlistalla's Hit Papers
Peers
Comparison fields: 5 of 60
- Oncology 602
- Cancer Research 252
- Pulmonary and Respiratory Medicine 187
- Cardiology and Cardiovascular Medicine 116
- Radiology, Nuclear Medicine and Imaging 89
Countries citing papers authored by A. Chlistalla
This map shows the geographic impact of A. Chlistalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Chlistalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Chlistalla more than expected).
Fields of papers citing papers by A. Chlistalla
This network shows the impact of papers produced by A. Chlistalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Chlistalla. The network helps show where A. Chlistalla may publish in the future.
Co-authors
The 25 scholars most cited alongside A. Chlistalla, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Hit paper breakdown → | 2010 | 700 |
| 2 | 1998 | 84 | |
| 3 | 1996 | 21 | |
| 4 | 2009 | 7 | |
| 5 | 2009 | 6 | |
| 6 | 2009 | 5 | |
| 7 | 2005 | 2 |
About A. Chlistalla
A. Chlistalla is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Pathology and Forensic Medicine, Cardiology and Cardiovascular Medicine and Cancer Research, having authored 7 papers that have together received 825 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), Advanced Breast Cancer Therapies (3 papers), Colorectal Cancer Treatments and Studies (2 papers), Breast Cancer Treatment Studies (2 papers), Cardiac electrophysiology and arrhythmias (2 papers), Lymphoma Diagnosis and Treatment (1 paper), Ion channel regulation and function (1 paper) and Monoclonal and Polyclonal Antibodies Research (1 paper). The work is most often cited by research in Oncology (602 citations), Cancer Research (252 citations), Pulmonary and Respiratory Medicine (187 citations), Cardiology and Cardiovascular Medicine (116 citations) and Radiology, Nuclear Medicine and Imaging (89 citations). A. Chlistalla has collaborated with scholars based in United Kingdom, Germany and Switzerland. Frequent co-authors include David Miles, Andrew Wardley, Andreas Schneeweiß, Arlene Chan, Xavier Pivot, Joohyuk Sohn, Piotr Tomczak, T. Delozier, Nadia Harbeck and Louise Provencher. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Circulation, Circulation Research and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.